Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New medical therapies for advanced left ventricular dysfunction

K Baughman1

  • 1Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD 21287, USA.

Cardiology Clinics
|February 1, 1995
PubMed
Summary

Current heart failure therapies are reviewed, with renin-angiotensin agents showing the most efficacy. Digoxin may benefit specific patients, while most calcium channel blockers are ineffective. Vesnarinone shows promise for improving mortality and symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HIV-associated myocarditis. Pathology and immunopathology.

The American journal of pathology·1990
Same author

The epidemiology of idiopathic dilated cardiomyopathy in a biracial community.

American journal of epidemiology·1990
Same author

Idiopathic dilated cardiomyopathy and atopic disease: epidemiologic evidence for an association with asthma.

American heart journal·1989
Same author

Prevalence of hyperlipidemia in heart transplant recipients.

Transplantation·1987
Same author

Pseudomonas aeruginosa tricuspid valve endocarditis: intraoperative use of ultraviolet light to confirm diagnosis.

The Journal of thoracic and cardiovascular surgery·1983

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Dilated cardiomyopathy and congestive heart failure treatments are evolving.
  • Understanding therapeutic targets is crucial for current and future drug development.

Purpose of the Study:

  • To analyze currently used therapeutic targets for heart failure.
  • To evaluate the efficacy and potential benefits of various drug classes.

Main Methods:

  • Review and analysis of existing therapeutic agents for heart failure.
  • Assessment of drug effects on mortality, symptoms, and specific physiological pathways.

Main Results:

  • Renin-angiotensin agents are the most efficacious.
  • Digoxin may benefit specific patient groups; most calcium channel blockers are ineffective.

Related Experiment Videos

  • Vesnarinone shows potential for improving mortality and symptoms, possibly due to anticytokine properties.

    • Conclusions:

    • Therapeutic strategies for heart failure require careful consideration of drug class and individual patient factors.
    • Newer agents and lower doses are under investigation, but evidence for some classes, like phosphodiesterase inhibitors, is limited for long-term use.